Expression and prognostic value of the WEE1 kinase in gliomas

Journal of Neuro-Oncology

Volumn 127, Issue 2, 2016, Pages 381-389

  Music, Darija ^a   Dahlrot, Rikke Hedegaard ^a   Hermansen, Simon Kjær ^a,b   Hjelmborg, Jacob ^b   de Stricker, Karin ^a   Hansen, Steinbjørn ^a,b   Kristensen, Bjarne Winther ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Biomarker; Glioblastoma; Glioma; Immunohistochemistry; Prognosis; WEE1

Indexed keywords

BIOLOGICAL MARKER; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN KINASE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; WEE1 PROTEIN; CELL CYCLE PROTEIN; DNA LIGASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN TYROSINE KINASE; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; WEE1 PROTEIN, HUMAN;

ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CELL NUCLEUS; CONTROLLED STUDY; DISEASE COURSE; DRUG TARGETING; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; GLIOMA; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; RADIOSENSITIVITY; TUMOR CELL; BRAIN NEOPLASMS; ENZYME IMMUNOASSAY; FOLLOW UP; METABOLISM; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE;

BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CELL CYCLE PROTEINS; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FOLLOW-UP STUDIES; GLIOMA; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM GRADING; NUCLEAR PROTEINS; PROGNOSIS; PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 84959867131     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-2050-4     Document Type: Article

References (31)

1. Louis DN, Ohgaki H, Wiestler OD et al (2007) WHO classification of tumours of the central nervous system, 4th edn. International Agency for Research on Cancer (IARC), Lyon
2. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466
3. Kesari S (2011) Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments. Semin Oncol 38:S2–S10
4. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492–507
5. Manning G, Whyte DB, Martinez R et al (2002) The protein kinase complement of the human genome. Science 298:1912–1934
6. De Witt Hamer PC, Mir SE, Noske D et al (2011) WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin Cancer Res 17:4200–4207
7. Mir SE, De Witt Hamer PC, Krawczyk PM et al (2010) In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 18:244–257
8. Wang Y, Li J, Booher RN et al (2001) Radiosensitization of p53 Mutant Cells by PD0166285, a Novel G2 Checkpoint Abrogator. Cancer Res 61:8211–8217
9. Iorns E, Lord CJ, Grigoriadis A et al (2009) Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS One 4:e5120
10. Masaki T, Shiratori Y, Rengifo W et al (2003) Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology 37:534–543
11. Blenk S, Engelmann JC, Pinkert MWS et al (2008) Explorative data analysis of MCL reveals gene expression networks implicated in survival and prognosis supported by explorative CGH analysis. BMC Cancer 8:106
12. Dahlrot RH, Kristensen BW, Hjelmborg J et al (2013) A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1. Int J Clin Exp Pathol 6:31–40
13. Dahlrot RH, Kristensen BW, Hjelmborg J et al (2013) A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1). J Neurooncol 114:309–317
14. Hermansen SK, Dahlrot RH, Nielsen BS et al (2013) MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas. J Neurooncol 111(1):71–81
15. Dahlrot RH, Hansen S, Herrstedt J et al (2013) Prognostic value of Musashi-1 in gliomas. J Neurooncol 115:453–461
16. Lathia JD, Li M, Sinyuk M (2014) High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor. Cell Rep 6(1):117–129
17. Dahlrot RH, Hansen S, Jensen SS et al (2014) Clinical value of CD133 and nestin in patients with glioma: a population-based study. Int J Clin Exp Pathol 7(7):3739–3751
18. PosthumaDeBoer J, Wurdinger T, Graat H et al (2011) WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer 11:156
19. Mueller S, Hashizume R, Yang X et al (2013) Targeting Wee1 for the treatment of pediatric high-grade gliomas. Neuro-Oncology 16(3):352–360
20. Harris PS, Venkataraman S, Alimova I et al (2014) Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma. Mol Cancer 13:1–14
21. Hong KS, Kim HS, Kim SH et al (2011) Hypoxia induces WEE1 expression and attenuates hydrogen peroxide-induced endothelial damage in MS1 cells. Exp Mol Med 43:653–659
22. Yoshida T, Tanaka S, Mogi A et al (2004) The clinical significance of cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol 15:252–256
23. Guertin AD, Li J, Liu Y et al (2013) Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy. Mol Cancer Ther 12:1442–1452
24. Kreahling JM, Gemmer JY, Reed D et al (2011) MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Mol Cancer Ther 11(1):174–182
25. Sarcar B, Kahali S, Prabhu AH et al (2011) Targeting radiation-induced G2 checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines. Mol Cancer Ther 10(12):2405–2414
26. Cancer Incidence by Age. Cancer Research UK. http://www.cancerresearchuk.org/cancer-info/cancerstats/incidence/age/. Accessed 26 Nov 2014
27. Do Cancer Rates Differ with Age? Australian Institute of Health and Welfare http://www.aihw.gov.au/cancer/. Accessed 26 Nov 2014
28. Finkel T, Serrano M, Blasco MA (2007) The common biology of cancer and ageing. Nature 448:767–774
29. Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64:479–489
30. Simon M, Hosen I, Gousias K et al (2015) TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro-Oncology 17:45–52
31. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003